[{"title":"WHO HIV Tx","nid":452,"rid":3041,"weight":0,"menu_type":"top_menu","next_nid":680,"deeperlink":[{"title":"Guidelines, Policy briefs and Meeting reports","nid":453,"rid":3082,"weight":-15,"icon":"","parent_nid":452,"menu_type":"menu_squares","field_checksum":"7babb5acd5ad95d0e7384770dde5f98eb7f5a6bee910334cde44efb372f9a248","deeperlink":[{"title":"Global health sector strategy","nid":661,"rid":3083,"weight":0,"parent_nid":453,"menu_type":"menu_list","field_checksum":"8d17c0827632a094aaa5212c80c6a479ccf24ce3b3ed9b4a464b9cdc94e482c0","deeperlink":[{"title":"Global health sector strategies on, respectively, HIV, viral hepatitis and sexually transmitted infections for the period 2022-2030","nid":680,"rid":3079,"weight":0,"parent_nid":661,"menu_type":"content","is_home":1,"field_checksum":"6bc3837cb589063c52052d6f21b587459a508f9d843882fcad19fcda8d02ce66","next_nid":456}]},{"title":"Consolidated guidelines 2021","nid":662,"rid":2947,"weight":1,"parent_nid":453,"menu_type":"menu_list","field_checksum":"66f88698e14b922c99e40ee23f0a2e5234c2e4ff45dc291c43f6411b8292f20d","deeperlink":[{"title":"Abbreviations and Acronyms","nid":456,"rid":2945,"weight":0,"parent_nid":662,"menu_type":"content","field_checksum":"44a9613e6778338ee16e741a6990f3bb4bf3671facfebc6f3989fc4fd0fe4ee1","prev_nid":680,"next_nid":504},{"title":"Acknowledgements","nid":504,"rid":3000,"weight":0,"parent_nid":662,"menu_type":"content","field_checksum":"58fd677655c12b944497f644caa35085185445212fe97c02fc71bf68eb0fe16d","prev_nid":456,"next_nid":457},{"title":"Executive Summary","nid":457,"rid":2951,"weight":2,"parent_nid":662,"menu_type":"content","field_checksum":"8186ef0b15e2fe5e4d33e69457ca12e79476608bbec2846c304d22f5f78f0ff4","prev_nid":504,"next_nid":468},{"title":"1. Introduction","nid":458,"rid":2952,"weight":3,"parent_nid":662,"menu_type":"menu_list","field_checksum":"064d9f2143d9ff194bcf70d1555ea726eaefdb747e4de424219db720bfde3480","deeperlink":[{"title":"1.1 Background and rationale","nid":468,"rid":1966,"weight":0,"parent_nid":458,"menu_type":"content","field_checksum":"498936804ee5250add6afaaad8c23aaba2e898acc924fd25d6861d7c8a8c98b5","prev_nid":457,"next_nid":469},{"title":"1.2 Objectives","nid":469,"rid":1967,"weight":0,"parent_nid":458,"menu_type":"content","field_checksum":"6b536aa7b68646c7beff71ac6730f699b524dcc8b9ec8d1b5a36b62214e6f4e3","prev_nid":468,"next_nid":470},{"title":"1.3 Target audience","nid":470,"rid":1959,"weight":0,"parent_nid":458,"menu_type":"content","field_checksum":"50c7610ac174c84324d471dead76bd2dd12cd191662e1e24994fe4ce03fbc8a3","prev_nid":469,"next_nid":471},{"title":"1.4 Guiding principles","nid":471,"rid":1960,"weight":0,"parent_nid":458,"menu_type":"content","field_checksum":"f9e4c19e6d4728e4bf80d34a77b53ecc663bcd0f8bf5b901960b547ed8c19d0b","prev_nid":470,"next_nid":473},{"title":"1.5 Methods for developing the guidelines","nid":472,"rid":2090,"weight":0,"parent_nid":458,"menu_type":"menu_list","field_checksum":"309ba5350b26be37680198c35f0fffa66c7dedfbc29a5e228ff75bee2533aea9","deeperlink":[{"title":"1.5.1 Guideline contributors","nid":473,"rid":1968,"weight":0,"parent_nid":472,"menu_type":"content","field_checksum":"03b41753372c4af47924d20a38c8fcebbd119396101e543a700584b8f63af474","prev_nid":471,"next_nid":474},{"title":"1.5.2 Competing interests","nid":474,"rid":1962,"weight":0,"parent_nid":472,"menu_type":"content","field_checksum":"154f5d8a71d5de7f01c76118d80e41da6da3bfb55973191770da327f72c110de","prev_nid":473,"next_nid":475},{"title":"1.5.3 Evidence synthesis","nid":475,"rid":1964,"weight":0,"parent_nid":472,"menu_type":"content","field_checksum":"50e0b890f19a56dbeeccb16acc1b851e433396c7cb1c565fc2718d57cccc7fdc","prev_nid":474,"next_nid":476},{"title":"1.5.4 Peer review","nid":476,"rid":1965,"weight":0,"parent_nid":472,"menu_type":"content","field_checksum":"211ec2f726c484efc0b9b88bde592b2ef2e0774b660e699f426e3da88ddec488","prev_nid":475,"next_nid":478}]},{"title":"1.6 Organization of the guidelines","nid":477,"rid":2091,"weight":0,"parent_nid":458,"menu_type":"menu_list","field_checksum":"544e6e9f2fca8d3f421a15a5f9ee35cb4198388fdfbff85e0a3e8b9453e8ea0d","deeperlink":[{"title":"1.6.1 Chapter contents","nid":478,"rid":2866,"weight":0,"parent_nid":477,"menu_type":"content","field_checksum":"da0a5415550041f9ccd55b7f5a992522c5ba42e89cd14f8985b87bd2ae7ec913","prev_nid":476,"next_nid":479},{"title":"1.6.2 Presentation of the recommendations","nid":479,"rid":1970,"weight":0,"parent_nid":477,"menu_type":"content","field_checksum":"8eeb3f137f48557c901a1a5c84d06d7d20c93ab95bd04d8f9cd1f357d45232ec","prev_nid":478,"next_nid":503}]},{"title":"References","nid":503,"rid":2045,"weight":0,"parent_nid":458,"menu_type":"content","field_checksum":"f824c1c4a820840fe7e12babeb1c5ca531410c2c38764a7ba35e88d6b4c20c96","prev_nid":479,"next_nid":480}]},{"title":"2. HIV Testing and Diagnosis","nid":459,"rid":2953,"weight":4,"parent_nid":662,"menu_type":"menu_list","field_checksum":"3cac338fd109a72c883d01f4a7fc0273e08e8ea160e028cd588ccf547e69fe76","deeperlink":[{"title":"2.1 Introduction","nid":480,"rid":1996,"weight":0,"parent_nid":459,"menu_type":"content","field_checksum":"fdc6202a9ea76b2dad90dc6a44999b7569369a83f5d944f9a2a6e145a45486ad","prev_nid":503,"next_nid":481},{"title":"2.2 HIV testing for a changing epidemic","nid":481,"rid":3004,"weight":0,"parent_nid":459,"menu_type":"content","field_checksum":"ab26ca36f0d5edbf1a81ea712f460efa26bf2322741a34d057ce3f57d8b634fd","prev_nid":480,"next_nid":482},{"title":"2.3 Mobilizing demand and pre-test services","nid":482,"rid":2920,"weight":0,"parent_nid":459,"menu_type":"content-menulist","field_checksum":"83afc9f007035122afc990d263175d888f8cf25533af23daf5d27db0806bcdd3","deeperlink":[{"title":"2.3.1 Pre-test services","nid":483,"rid":2690,"weight":0,"parent_nid":482,"menu_type":"content","field_checksum":"58238dcb139c46f06cfda63c2c2690c20281d6b900845a6d8c27e7349dc1ea60","prev_nid":482,"next_nid":485}],"prev_nid":481,"next_nid":483},{"title":"2.4 HIV testing service delivery approaches","nid":485,"rid":2006,"weight":0,"parent_nid":459,"menu_type":"content","field_checksum":"2a3c56174e571ea2ba5f5dec71cf73e78c6df8b819f332192300a29ef78d2bcb","deeperlink":[{"title":"2.4.1 Facility-based HIV testing services","nid":486,"rid":2895,"weight":0,"parent_nid":485,"menu_type":"content","field_checksum":"8f737dac5810461dbedd21841f7b09e542f938dd9ee2f07be8b70fc2f607ed84","prev_nid":485,"next_nid":487},{"title":"2.4.2 Facility-based HIV testing for infants and children","nid":487,"rid":2071,"weight":0,"parent_nid":485,"menu_type":"content","field_checksum":"96d0c87849ef019b82f24c90f48e593de365b3a0b9f9a7394fe84dea6586ec81","prev_nid":486,"next_nid":488},{"title":"2.4.3 Community-based HIV testing services","nid":488,"rid":2896,"weight":0,"parent_nid":485,"menu_type":"content","field_checksum":"34e3623423b18bfcc3e659671105ddeb00fc6513d517d0b2fcabf1e39718e774","prev_nid":487,"next_nid":489},{"title":"2.4.4 HIV self-testing","nid":489,"rid":2828,"weight":0,"parent_nid":485,"menu_type":"content","field_checksum":"3b9c3213898b7326fd5180866ac200fa8041517985f62b7f72213aadba33a7a8","prev_nid":488,"next_nid":490},{"title":"2.4.5 HIV partner services","nid":490,"rid":2692,"weight":0,"parent_nid":485,"menu_type":"content","field_checksum":"22aa3efbe700613bcf80880366a49f017a0243b7f9a7b5abf95bee7c8c43b952","prev_nid":489,"next_nid":491},{"title":"2.4.6 Strategic planning for HIV testing services","nid":491,"rid":2693,"weight":0,"parent_nid":485,"menu_type":"content","field_checksum":"5d4ec00c238798116d4a5900a5b5967cb2ceb46364ac476890b2fd222e10ca1b","prev_nid":490,"next_nid":492},{"title":"2.4.7 Implementation considerations for priority populations","nid":492,"rid":2748,"weight":0,"parent_nid":485,"menu_type":"content","field_checksum":"4e0e0cb1fb7c7cb143d3a2e3cf2d5d5b83cefbeebfcd9b53145608823b68f45f","prev_nid":491,"next_nid":493}],"prev_nid":483,"next_nid":486},{"title":"2.5 Post-test services and linkage to prevention, treatment and other services","nid":493,"rid":2749,"weight":0,"parent_nid":459,"menu_type":"content","field_checksum":"3b1958b0b0547f992aeb8eb4d0536fc7cbbac0f7dbd0358e4020523a3f9614b3","prev_nid":492,"next_nid":494},{"title":"2.6 Strategies to make HIV testing services accessible","nid":494,"rid":2080,"weight":0,"parent_nid":459,"menu_type":"content","field_checksum":"48a8e4a213b5ec8e3c4928293cd7ce76c008adb9b5c07fe2915aa15b2a6cf6a7","prev_nid":493,"next_nid":495},{"title":"2.7 Maintaining the accuracy and reliability of HIV diagnosis","nid":495,"rid":2751,"weight":0,"parent_nid":459,"menu_type":"content","field_checksum":"56b913f0f49e1866a96326c4a9bdca814517d3188a46196e2197d49336c31955","prev_nid":494,"next_nid":496},{"title":"2.8 HIV diagnosis among infants and children","nid":496,"rid":2752,"weight":0,"parent_nid":459,"menu_type":"content","field_checksum":"daf8aa1930079fd5f0a52f04b18de1022eab9a5fba4639ade080f19cdee2adc2","deeperlink":[{"title":"2.8.1 Timing of virological testing","nid":497,"rid":2696,"weight":0,"parent_nid":496,"menu_type":"content","field_checksum":"41e6afa3cef12e8d0f9c5ad270397fd30a241d4d5583b9d5460416f72345a776","prev_nid":496,"next_nid":498},{"title":"2.8.2 Infant diagnosis algorithm","nid":498,"rid":2753,"weight":0,"parent_nid":496,"menu_type":"content","field_checksum":"eb325153ad8d5dbd6ceedca5233a38ed915703be4f3e200db0851e621c4c2e74","prev_nid":497,"next_nid":499},{"title":"2.8.3 Technologies to use for infant testing","nid":499,"rid":2698,"weight":0,"parent_nid":496,"menu_type":"content","field_checksum":"f40bbb01d7fff529f791957a67818650bfb603105d1a382af6c86767cf4c1bdf","prev_nid":498,"next_nid":500},{"title":"2.8.4 Rapid diagnostic tests for HIV serology","nid":500,"rid":2754,"weight":0,"parent_nid":496,"menu_type":"content","field_checksum":"d457849f660820122c2b0c061d9a8ff048f46ac78e13a355135a133ca031deff","prev_nid":499,"next_nid":501},{"title":"2.8.6 Minimizing false-positive results by introducing an indeterminate range for infant diagnosis when using NAT","nid":501,"rid":2756,"weight":0,"parent_nid":496,"menu_type":"content","field_checksum":"691cba801d8ec1b198a72e34fce59c11bcf43a51abc57c186789c088d001f9ad","prev_nid":500,"next_nid":502},{"title":"2.8.7 Managing discordant results and treatment interruption","nid":502,"rid":2757,"weight":0,"parent_nid":496,"menu_type":"content","field_checksum":"6e0b70e7ed6387507972dd7b69cad76c3c29619398f89c0403cc7d7284e4a923","prev_nid":501,"next_nid":514}],"prev_nid":495,"next_nid":497},{"title":"References","nid":514,"rid":2913,"weight":0,"parent_nid":459,"menu_type":"content","field_checksum":"caee819a7fe5e57cdbd34f4878cacb3c73be439e050440ca2dc987a3f766e8f6","prev_nid":502,"next_nid":507}]},{"title":"3. HIV Prevention","nid":460,"rid":2954,"weight":5,"parent_nid":662,"menu_type":"menu_list","field_checksum":"a062ba77eaed73f7c9bf9f344efa519ebf74fffb006363f6c7d1f0214c8a0c67","deeperlink":[{"title":"3.1 Combination HIV prevention","nid":507,"rid":3006,"weight":0,"parent_nid":460,"menu_type":"content","field_checksum":"1432a4793e5d5d8189d3a1df9fa4592a241023eb077f6571ad7ef8a39e217c8e","prev_nid":514,"next_nid":508},{"title":"3.2 Pre-exposure prophylaxis for preventing the acquisition of HIV","nid":508,"rid":2726,"weight":0,"parent_nid":460,"menu_type":"content-menulist","field_checksum":"08db02a14066648cccb01d0f70470572d0fae256d8921ceebd9d165d7c76a647","deeperlink":[{"title":"3.2.1 Oral pre-exposure prophylaxis for preventing the acquisition of HIV","nid":511,"rid":3007,"weight":0,"parent_nid":508,"menu_type":"content","field_checksum":"6b9cf55f895b92c387d5f3b0184dcc79949d4b76140942a238fa470b3c233f83","prev_nid":508,"next_nid":512},{"title":"3.2.2 PrEP using the dapivirine vaginal ring","nid":512,"rid":2872,"weight":0,"parent_nid":508,"menu_type":"content","field_checksum":"f442b51d4e1db55c39887e5c132dbabd93caf4815d4f2a901e1382ab7ff46863","prev_nid":511,"next_nid":509}],"prev_nid":507,"next_nid":511},{"title":"3.3 Post-exposure prophylaxis","nid":509,"rid":2758,"weight":0,"parent_nid":460,"menu_type":"content","field_checksum":"c1fbaffeba958cb7cbec0f20a9555cb55c93cfaaf35987ee5469fefda5f844db","prev_nid":512,"next_nid":510},{"title":"3.4 Infant prophylaxis","nid":510,"rid":2910,"weight":0,"parent_nid":460,"menu_type":"content","field_checksum":"8e39e3cc612c223ec95e34185bedd8b94dfd982aa0b75332b4a4da3ad8fe1a82","prev_nid":509,"next_nid":515}]},{"title":"4. Antiretroviral Therapy","nid":461,"rid":2955,"weight":6,"parent_nid":662,"menu_type":"menu_list","field_checksum":"8829f7302b63c8520de090c73e213aabe1c617ddfc27c6ebed36a4459aeec310","deeperlink":[{"title":"4.1 Introduction","nid":515,"rid":2149,"weight":0,"parent_nid":461,"menu_type":"content","field_checksum":"d36bf70a336e6d03244aa248e17994725c8357c5451d68c951b31454ad3214d3","prev_nid":510,"next_nid":516},{"title":"4.2 Preparing people living with HIV for ART","nid":516,"rid":2180,"weight":0,"parent_nid":461,"menu_type":"content","field_checksum":"c0d2e871b4ab82278892cfd5eccc543bfd0af923a3e6d8be6985b4b9c44a4503","prev_nid":515,"next_nid":517},{"title":"4.3 What to expect in the first months of ART","nid":517,"rid":2760,"weight":0,"parent_nid":461,"menu_type":"content","field_checksum":"f9bc92f5ec5c12f525d88721c2aa01c34888ca66c02c02156ffa9f225f34de05","prev_nid":516,"next_nid":518},{"title":"4.4 When to start ART","nid":518,"rid":2211,"weight":0,"parent_nid":461,"menu_type":"content","field_checksum":"45859e0f59eb1af7200a67cd5ee43d55abf0e28fcd65e5ab8c6603eadc8fa465","prev_nid":517,"next_nid":520},{"title":"4.5 Timing of ART","nid":519,"rid":2730,"weight":0,"parent_nid":461,"menu_type":"menu_list","field_checksum":"1a1b7e0137c0393595e21c37a96a9e4e1408c617e0bd207c55b02ffe9585b15a","deeperlink":[{"title":"4.5.1 Rapid ART initiation","nid":520,"rid":2761,"weight":0,"parent_nid":519,"menu_type":"content","field_checksum":"fa3a4f4968a9f2214a1156cafeace57b78f603a153f8c947688c0d1fae4edbf1","prev_nid":518,"next_nid":521},{"title":"4.5.2 Timing of ART for adults, adolescents and children being treated for HIV-associated TB","nid":521,"rid":2874,"weight":0,"parent_nid":519,"menu_type":"content","field_checksum":"df987c08c91c1f119fee7332dfe0c3017e21fe97198798f5d5e910ac2954c332","prev_nid":520,"next_nid":522},{"title":"4.5.3 Timing of ART for people living with HIV and cryptococcal meningitis","nid":522,"rid":2246,"weight":0,"parent_nid":519,"menu_type":"content","field_checksum":"faad8fcdb6c077d3a181ba61cf744cd808703b7ce9393d99701e99c6fb4ab915","prev_nid":521,"next_nid":523},{"title":"4.5.4 Timing of ART for people living with HIV and histoplasmosis","nid":523,"rid":2247,"weight":0,"parent_nid":519,"menu_type":"content","field_checksum":"16bb0d5900ed50c5e2422ddb351d16ff8e3f4b1d2168bcb5583ae80913ec681d","prev_nid":522,"next_nid":525}]},{"title":"4.6 What to start","nid":524,"rid":2731,"weight":0,"parent_nid":461,"menu_type":"menu_list","field_checksum":"d3fab43eaf14dfdaf1eef1fd91aaa59411db7ef2f2691bc311aab57751f228a7","deeperlink":[{"title":"4.6.1 First-line ART","nid":525,"rid":2912,"weight":0,"parent_nid":524,"menu_type":"content","field_checksum":"55dcc9c84c45ef363b6ca259fa1f4523846a00a69e5e4e9f56aba9010262c848","prev_nid":523,"next_nid":526},{"title":"4.6.2 Second-line ART","nid":526,"rid":2764,"weight":0,"parent_nid":524,"menu_type":"content","field_checksum":"f552057af3527de7bae698b5f4ad702ed63abd5bef9c458a74032e39421e4618","prev_nid":525,"next_nid":527},{"title":"4.6.3 Third-line ART","nid":527,"rid":2875,"weight":0,"parent_nid":524,"menu_type":"content","field_checksum":"d2efea1590f9262bd6f45de587da2b1aeceb3200b8ce744a19e2ffb17466a5c0","prev_nid":526,"next_nid":528}]},{"title":"4.7 Monitoring the response to ART","nid":528,"rid":2766,"weight":0,"parent_nid":461,"menu_type":"content-menulist","field_checksum":"25880783bf11ffbcc97f01c6ad7744b2c8ebf65467233883bce2bb59017c9281","deeperlink":[{"title":"4.7.1 Monitoring after initiating ART","nid":529,"rid":2767,"weight":0,"parent_nid":528,"menu_type":"content","field_checksum":"7dc3bc445e7b33b45075fba8fc56690035d848de16b1b5ec68b5db72070cc295","prev_nid":528,"next_nid":530},{"title":"4.7.2 Treatment monitoring of ART","nid":530,"rid":2876,"weight":0,"parent_nid":528,"menu_type":"content","field_checksum":"bcb8ed0f0b5a5b8bf179eeab41b7801b57ba5c82d8302efa28aade56d44cf7f2","prev_nid":529,"next_nid":531},{"title":"4.7.3 Point-of-care viral load testing","nid":531,"rid":2305,"weight":0,"parent_nid":528,"menu_type":"content","field_checksum":"b603fc4dc89ce99b4d918f56633d987d9d2dd3a6337562f19103ff5e67f1eb3a","prev_nid":530,"next_nid":532},{"title":"4.7.4 Other clinical and diagnostic considerations","nid":532,"rid":2306,"weight":0,"parent_nid":528,"menu_type":"content","field_checksum":"6870130395ade58ef0c7eae885bc017c81c47b61822ecce7a51a22afcff14919","prev_nid":531,"next_nid":533},{"title":"4.7.5 Monitoring ARV drug resistance","nid":533,"rid":2241,"weight":0,"parent_nid":528,"menu_type":"content","field_checksum":"dd74f385c8d1035e5a37727cc5d2f66e72935fbe35ab925601aa089e102ee742","prev_nid":532,"next_nid":534}],"prev_nid":527,"next_nid":529},{"title":"4.8 Monitoring ARV toxicity","nid":534,"rid":2728,"weight":0,"parent_nid":461,"menu_type":"content-menulist","field_checksum":"334eb0f02fc19502f06c24f084d0c27d1cdd61a83d366484f245408f0822b714","deeperlink":[{"title":"4.8.1 Major types of ARV toxicity","nid":535,"rid":2769,"weight":0,"parent_nid":534,"menu_type":"content","field_checksum":"7a8547001e870c96a100dd1143b60d89f0541e0d542af71e0b5db49572c53b2a","prev_nid":534,"next_nid":536},{"title":"4.8.2 Safety of DTG during pregnancy","nid":536,"rid":2309,"weight":0,"parent_nid":534,"menu_type":"content","field_checksum":"88d849585443233cc4957e18caef9b02e6ff597d20aad2c8318654dbbe7faaf6","prev_nid":535,"next_nid":537},{"title":"4.8.3. Monitoring DTG toxicity","nid":537,"rid":2310,"weight":0,"parent_nid":534,"menu_type":"content","field_checksum":"3b7417d6e25c3579671baa81386011ca3bf0f9248ae69ff9b026d3c8add18f53","prev_nid":536,"next_nid":538},{"title":"4.8.4 Monitoring the toxicity of ARV drugs among adolescents, children and neonates","nid":538,"rid":2244,"weight":0,"parent_nid":534,"menu_type":"content","field_checksum":"4e4436ee63d17d85b0cdb5eddb618e903030b2f5c453f84abd0959139e165c05","prev_nid":537,"next_nid":539},{"title":"4.8.5 Drug substitutions for ARV drug toxicity","nid":539,"rid":2770,"weight":0,"parent_nid":534,"menu_type":"content","field_checksum":"d48b63734536b669a6af44a827ff6827cc588d86078812f0c6f092b5328cb3bd","prev_nid":538,"next_nid":540}],"prev_nid":533,"next_nid":535},{"title":"4.9 ARV drug resistance","nid":540,"rid":2771,"weight":0,"parent_nid":461,"menu_type":"content","field_checksum":"9286b6c4bf2a4cc3ab3ff9e0638dfcb28ac6c6a9fe1bc382634cbbea6e9e9d11","prev_nid":539,"next_nid":541},{"title":"4.10 Key ARV drug interactions","nid":541,"rid":2313,"weight":9,"parent_nid":461,"menu_type":"content","field_checksum":"9932369557bcbc0c30c319d4ad83d2916fdda03faf3a0aba84529c2033dc1875","prev_nid":540,"next_nid":542},{"title":"References","nid":542,"rid":2720,"weight":10,"parent_nid":461,"menu_type":"content","field_checksum":"9a4ce91d14e91472fc200ef95f401969a1904fe582167c35f6ae47a2b7d195e0","prev_nid":541,"next_nid":462}]},{"title":"5. Managing Advanced HIV Disease","nid":462,"rid":2956,"weight":7,"parent_nid":662,"menu_type":"content-menulist","field_checksum":"67c99d17953687315d8ced2cc0f1fc2cea0ae0d346bd5cac142126f74278ce6a","deeperlink":[{"title":"5.1 Introduction","nid":543,"rid":2274,"weight":0,"parent_nid":462,"menu_type":"content","field_checksum":"cf39e995287aef37a936287b29d479e5842ee3ea594cbf9f28676344e1ea4c5c","prev_nid":462,"next_nid":544},{"title":"5.2 Causes of morbidity and mortality among adults with advanced HIV disease","nid":544,"rid":2877,"weight":0,"parent_nid":462,"menu_type":"content","field_checksum":"d710caf55f09742728c629abb6b619e002342d515e7b7bad82a7800edd8d2f28","prev_nid":543,"next_nid":545},{"title":"5.3 Providing a package of care","nid":545,"rid":2772,"weight":0,"parent_nid":462,"menu_type":"content","field_checksum":"bfede56ad0d596f18fb15e6781d6bb0469119eba62d36d97267066837bb1f89a","prev_nid":544,"next_nid":546},{"title":"5.4 Overview of clinical management of cryptococcal disease","nid":546,"rid":2774,"weight":0,"parent_nid":462,"menu_type":"content","field_checksum":"c3259482f1c9bb5f82f44bef72d05193027c8e4e1b5cbecee9c3fbc69283e259","prev_nid":545,"next_nid":547},{"title":"5.5 Overview of clinical management of histoplasmosis","nid":547,"rid":2775,"weight":0,"parent_nid":462,"menu_type":"content","field_checksum":"7a4dc03b94818e65bd474180338be8f27c6c834d59c65906288915aaa2f896cc","prev_nid":546,"next_nid":548},{"title":"5.6 Advanced HIV disease among children and adolescents","nid":548,"rid":2878,"weight":0,"parent_nid":462,"menu_type":"content","field_checksum":"8e275229f95f076ca60782c33dabf8dd0291481e2baf302f79571f51e169f5d8","prev_nid":547,"next_nid":549},{"title":"5.7 Supporting decision-making for providing a package of care","nid":549,"rid":2733,"weight":0,"parent_nid":462,"menu_type":"content-menulist","field_checksum":"9a04239b49b55075ebfc0db7245200d935845f9ce69f490e6c90015b7977be25","deeperlink":[{"title":"5.7.1 People re-engaging with care after treatment interruption or treatment failure","nid":550,"rid":2321,"weight":0,"parent_nid":549,"menu_type":"content","field_checksum":"7401625902d66fd8fedef2774c6ea9643b7bd6f7b1183b5e593b80bc750cb076","prev_nid":549,"next_nid":551},{"title":"5.7.2 Vaccination for people with advanced HIV disease","nid":551,"rid":2328,"weight":0,"parent_nid":549,"menu_type":"content","field_checksum":"898ce9c370fba0a821e1458fcfb849fd87690beeb868ea6f4801e0877c2dc2e6","prev_nid":550,"next_nid":552}],"prev_nid":548,"next_nid":550},{"title":"5.8 Programme considerations","nid":552,"rid":2777,"weight":0,"parent_nid":462,"menu_type":"content","field_checksum":"a4494153708a7f39b23db9a9ca919af550be246194a2eb8bf71f8d17fee9b719","prev_nid":551,"next_nid":553},{"title":"References","nid":553,"rid":2294,"weight":0,"parent_nid":462,"menu_type":"content","field_checksum":"89c0fd2fae7c245cbad1cdd40b6fef30c1b2cc50237e6391a870c68f5cddc3e0","prev_nid":552,"next_nid":554}],"prev_nid":542,"next_nid":543},{"title":"6. General Care and Managing Common Coinfectons and Comorbidities","nid":463,"rid":2957,"weight":8,"parent_nid":662,"menu_type":"menu_list","field_checksum":"197800b4126ea313c49a6a9ad96808de8c2200223a9851e231a1d83eb9cc4a85","deeperlink":[{"title":"6.1 Introduction","nid":554,"rid":2419,"weight":-15,"parent_nid":463,"menu_type":"content","field_checksum":"f937c1e0f93969073f137a43c7dd1182e6122907c651af7882e5c015ec347aa6","prev_nid":553,"next_nid":555},{"title":"6.2 General care for people living with HIV","nid":555,"rid":2908,"weight":-14,"parent_nid":463,"menu_type":"content","field_checksum":"0c4eea3a50f1963865b80347be4ad6f02c34b91d038996269f339afc22b351b5","prev_nid":554,"next_nid":556},{"title":"6.3 Co-trimoxazole prophylaxis","nid":556,"rid":2780,"weight":-13,"parent_nid":463,"menu_type":"content","field_checksum":"9faa18369b21a05aa79423bbb757af5ec642d7dc9bd734217e6000417e250c56","prev_nid":555,"next_nid":557},{"title":"6.4 Tuberculosis","nid":557,"rid":2734,"weight":-12,"parent_nid":463,"menu_type":"content-menulist","field_checksum":"f430d80e29c3e126e41629dbdb09b203f1e1760e236b69975e73c403a19ad8aa","deeperlink":[{"title":"6.4.1 Screening and diagnosis","nid":558,"rid":2879,"weight":0,"parent_nid":557,"menu_type":"content","field_checksum":"44db6db80d8bb2d189e2ef7eacec6c40065bb43a26aa9170eeaf4a9100086beb","prev_nid":557,"next_nid":559},{"title":"6.4.2 Timing of ART for adults and children with TB","nid":559,"rid":2348,"weight":0,"parent_nid":557,"menu_type":"content","field_checksum":"ab023dddc013c4a3db37bd456dae717c0d1ecfd0c519e20530ab7428a6193fa7","prev_nid":558,"next_nid":560},{"title":"6.4.3 Treatment","nid":560,"rid":2715,"weight":0,"parent_nid":557,"menu_type":"content","field_checksum":"4f33a4542b95f685f5768764bf7c91e71c21ea931c49403104586cb0fc36ede3","prev_nid":559,"next_nid":561},{"title":"6.4.4 Prevention","nid":561,"rid":2722,"weight":0,"parent_nid":557,"menu_type":"content","field_checksum":"85e648c029c01c6f4f2f0e82e1f3401b030a2955fbf4a8efec7baf84ae72a767","prev_nid":560,"next_nid":562},{"title":"6.4.5 Infection control","nid":562,"rid":2426,"weight":0,"parent_nid":557,"menu_type":"content","field_checksum":"fe9705c41c6a17a473b42a14763ea819902a56ce9f7c37dd001947b9e988cf80","prev_nid":561,"next_nid":563}],"prev_nid":556,"next_nid":558},{"title":"6.5 Hepatitis B and C","nid":563,"rid":2729,"weight":-11,"parent_nid":463,"menu_type":"content-menulist","field_checksum":"d64e390fb12ad8832afb6592e5b3fe0094e88647636869419022889a76d820b0","deeperlink":[{"title":"6.5.1 HIV and HBV or HCV coinfection","nid":564,"rid":2428,"weight":0,"parent_nid":563,"menu_type":"content","field_checksum":"c173dec8ddc6b8a5bf59d2b29450add53b9684740582fb0195e30e3da6394733","prev_nid":563,"next_nid":565},{"title":"6.5.2 Testing for HBV and HCV infection","nid":565,"rid":2723,"weight":0,"parent_nid":563,"menu_type":"content","field_checksum":"77a70391411c15e99e82a0c5930188aa7b25961a39e2617536e3720afb78e215","prev_nid":564,"next_nid":566},{"title":"6.5.3 Managing HIV and HCV coinfection","nid":566,"rid":2782,"weight":0,"parent_nid":563,"menu_type":"content","field_checksum":"2d666d95d23f1cb1abb8a679b6dd98061014f39ec156cad7eab0f512dbedac2f","prev_nid":565,"next_nid":567},{"title":"6.5.4 Managing HIV and HBV coinfection","nid":567,"rid":2431,"weight":0,"parent_nid":563,"menu_type":"content","field_checksum":"9b6bb3a0674ef6b3061062da08fa0d44974a8a82bece1b21794c1f1e70b4050b","prev_nid":566,"next_nid":568},{"title":"6.5.5 Preventing mother-to-child transmission of HBV infection","nid":568,"rid":2783,"weight":0,"parent_nid":563,"menu_type":"content","field_checksum":"9c86bd2af6df9e39b8a1dda380bb15af52cf05a745e35a8a94d46b4d8dcd1d02","prev_nid":567,"next_nid":569}],"prev_nid":562,"next_nid":564},{"title":"6.6 Malaria","nid":569,"rid":2461,"weight":-10,"parent_nid":463,"menu_type":"content","field_checksum":"a90e9d01cc263e12c1dd24c186f5f04b204228a19dde03a8508c6ee8856f5a69","prev_nid":568,"next_nid":570},{"title":"6.7 Buruli ulcer","nid":570,"rid":2462,"weight":-9,"parent_nid":463,"menu_type":"content","field_checksum":"5daabeb27945a953619c04be35215b1df911550a154638a4b573937d062d8fed","prev_nid":569,"next_nid":571},{"title":"6.8 Leishmaniasis","nid":571,"rid":2463,"weight":-8,"parent_nid":463,"menu_type":"content","field_checksum":"f5604e9842efd8fb4f5869f09d591ba59044c69b525ce07159dcd4730ca052d7","prev_nid":570,"next_nid":572},{"title":"6.9 Cervical cancer","nid":572,"rid":2784,"weight":-7,"parent_nid":463,"menu_type":"content","field_checksum":"eccced0b609010e4acc69a9cd075df7154604c4d602f39a8d619a2320e8c3911","prev_nid":571,"next_nid":573},{"title":"6.10 Noncommunicable diseases","nid":573,"rid":2465,"weight":-6,"parent_nid":463,"menu_type":"content","field_checksum":"95176b4096cc2a71b5ee023000669eba8a2f933ab7a807f90cb2bb38926f1631","prev_nid":572,"next_nid":574},{"title":"6.11 Mental health among people living with HIV","nid":574,"rid":2466,"weight":-5,"parent_nid":463,"menu_type":"content","field_checksum":"4cf8776527ee939c6f6019c5a1600879ce51a933544b926758c6b0458a08fe1a","prev_nid":573,"next_nid":575},{"title":"6.12 Drug use","nid":575,"rid":2880,"weight":-4,"parent_nid":463,"menu_type":"content","field_checksum":"3cdfe29fc2e463539051006874f4de7d76008bd0e227215ebb22adbd973677d4","prev_nid":574,"next_nid":576},{"title":"6.13 Sexually transmitted infections","nid":576,"rid":2884,"weight":-3,"parent_nid":463,"menu_type":"content","field_checksum":"0a83b6f364b5e7861cfd712fd46270f06912a8196cc1f5ace18d1e635e06fc47","prev_nid":575,"next_nid":577},{"title":"6.14 Vaccines for people living with HIV","nid":577,"rid":2785,"weight":-2,"parent_nid":463,"menu_type":"content","field_checksum":"c5b9479cffe862b11d22f39d7151122712696d2326501f9f7ee67aa5315a46cf","prev_nid":576,"next_nid":578},{"title":"6.15 HIV-related skin and oral conditions","nid":578,"rid":2442,"weight":-1,"parent_nid":463,"menu_type":"content","field_checksum":"1c04f666e65022dcfebe4dd845f9e84b3c3792e1f4288195eceac910e09d8a7a","prev_nid":577,"next_nid":579},{"title":"6.16 Nutritional care and support","nid":579,"rid":2443,"weight":0,"parent_nid":463,"menu_type":"content","field_checksum":"b4f1c4068f941aecba7bc4f0e5ff52eecffb8d761e956495ea24359755102de3","deeperlink":[{"title":"6.16.1 Infant feeding in the context of HIV","nid":580,"rid":2470,"weight":0,"parent_nid":579,"menu_type":"content","field_checksum":"c5357f22ed85e0d949f056c3ea5e846c826a66523b7b06aece0acd2be043935c","prev_nid":579,"next_nid":581}],"prev_nid":578,"next_nid":580},{"title":"6.17 Palliative care","nid":581,"rid":2471,"weight":1,"parent_nid":463,"menu_type":"content","field_checksum":"a054a2333692da08561ee324463f81a211d100168c89fb8e0a7cf15e79d54927","prev_nid":580,"next_nid":582},{"title":"6.18 Noncommunicable diseases among children and adolescents","nid":582,"rid":2900,"weight":2,"parent_nid":463,"menu_type":"content","field_checksum":"e8aa940246797167378a30cf734064827b6b1b79ab1624790ed8e2fbe282939a","prev_nid":581,"next_nid":583},{"title":"References","nid":583,"rid":2901,"weight":3,"parent_nid":463,"menu_type":"content","field_checksum":"1cedd4e7002306e5e38d7c372dec5b8294cbcdff3923ca039f93b0a16a2afc86","prev_nid":582,"next_nid":584}]},{"title":"7. Service Delivery","nid":464,"rid":2958,"weight":9,"parent_nid":662,"menu_type":"menu_list","field_checksum":"ccee2127a1ca10f820df1a0aebe5091c3bd2d270a94b039ffcf78e3cc286497e","deeperlink":[{"title":"7.1 Introduction","nid":584,"rid":2595,"weight":0,"parent_nid":464,"menu_type":"content","field_checksum":"b074b7a394fd546b8ab327f4e94f756bf835aff91096b20b4a61fa3144e4e8db","prev_nid":583,"next_nid":585},{"title":"7.2 Linkage from HIV testing to enrolment in care","nid":585,"rid":2600,"weight":0,"parent_nid":464,"menu_type":"content","field_checksum":"ccfa1c9d75000b0be0abc6a4a6c8e89116e209d516284ead988cb1818a434aff","prev_nid":584,"next_nid":586},{"title":"7.3 Differentiated service delivery for HIV treatment","nid":586,"rid":2902,"weight":0,"parent_nid":464,"menu_type":"content","field_checksum":"c752eb459c8aeaeb5f61f62b2890276b22c867313b0b98201884bb2e5c00b876","prev_nid":585,"next_nid":587},{"title":"7.4 People-centred care","nid":587,"rid":3003,"weight":0,"parent_nid":464,"menu_type":"content","field_checksum":"376003fcda4a5cbeda76ba64dc880db4ddcf83ee0639b4a46240f7d174b0f6ea","prev_nid":586,"next_nid":599},{"title":"7.5 Initiating and maintaining treatment","nid":588,"rid":2735,"weight":0,"parent_nid":464,"menu_type":"menu_list","field_checksum":"6f1fe65a8189cda38f2b71862669051217e2d49408328608583098d05bc553b4","deeperlink":[{"title":"7.5.1 Initiating ART outside the health facility","nid":599,"rid":2604,"weight":0,"parent_nid":588,"menu_type":"content","field_checksum":"9d84c835a26f63e1afeec2acfc63ed4feb4e3b02dcb0dbd491c63f9292361421","prev_nid":587,"next_nid":600},{"title":"7.5.2 Rapid initiation of ART, including same-day start","nid":600,"rid":2788,"weight":0,"parent_nid":588,"menu_type":"content","field_checksum":"4f18aaca9f03699e744164bb9941a4e4211253656a705bf86429a221bc741858","prev_nid":599,"next_nid":601},{"title":"7.5.3 Frequency of clinical visits and ART pick-up","nid":601,"rid":2606,"weight":0,"parent_nid":588,"menu_type":"content","field_checksum":"a0bcc317db821c619ca06d175be191acdc9f213c6d3d473fbd70dccbc59317bc","prev_nid":600,"next_nid":602},{"title":"7.5.4 Adherence support","nid":602,"rid":2885,"weight":0,"parent_nid":588,"menu_type":"content","field_checksum":"e3ff7a96cd728af286079057410cbd80b7dd0dd57d621ef48df4e7f7f256a4cd","prev_nid":601,"next_nid":603},{"title":"7.5.5 Monitoring adherence to ART in routine programme and care settings","nid":603,"rid":2608,"weight":0,"parent_nid":588,"menu_type":"content","field_checksum":"11f9f12b682cfc0641789fe08c074d785c9f92868eb48b0a03d1c39913b0bc15","prev_nid":602,"next_nid":604}]},{"title":"7.6 Continuity of care","nid":589,"rid":2736,"weight":0,"parent_nid":464,"menu_type":"menu_list","field_checksum":"4a7a45a445d24941a34799125fafb79066b2f6adc891be41f5a57a414763418b","deeperlink":[{"title":"7.6.1 Retention in care","nid":604,"rid":2886,"weight":0,"parent_nid":589,"menu_type":"content","field_checksum":"7fb32d1b24f05c402963f008a88e22c2ec5526ead90fc12515aa6ec6e7412f48","prev_nid":603,"next_nid":605},{"title":"7.6.2 Tracing and re-engagement in care","nid":605,"rid":2611,"weight":0,"parent_nid":589,"menu_type":"content","field_checksum":"cefbdb631f705a9bf3d1ae1af2139f14ddb22d1cb3b4c3b28a6fe2dce99e9da2","prev_nid":604,"next_nid":606}]},{"title":"7.7 Task sharing","nid":590,"rid":2737,"weight":0,"parent_nid":464,"menu_type":"menu_list","field_checksum":"b0a5d02ee27d78534b8fd6dd8b713edc20012af9c25271ed2f5ae2c1c04dfa4b","deeperlink":[{"title":"7.7.1 Task sharing for initiating and maintaining ART","nid":606,"rid":2612,"weight":0,"parent_nid":590,"menu_type":"content","field_checksum":"458f6cef1ff8d8fa99a4ccd187e4222f5de9611af6bac01d2f34f4c30769135a","prev_nid":605,"next_nid":607},{"title":"7.7.2 Task sharing of specimen collection and point-of-care testing","nid":607,"rid":2613,"weight":0,"parent_nid":590,"menu_type":"content","field_checksum":"354f52ba7e6cf53f9f134b9bfc3239bc81bd697c8e60097df1aabe2cfaeb269a","prev_nid":606,"next_nid":591}]},{"title":"7.8 Decentralization","nid":591,"rid":2614,"weight":0,"parent_nid":464,"menu_type":"content","field_checksum":"120e3ffa63ac3ad5d9d3f5f542775fcdbe303efcd91358b45cfebd632ac678f4","prev_nid":607,"next_nid":592},{"title":"7.9 Integrating services","nid":592,"rid":2738,"weight":0,"parent_nid":464,"menu_type":"content-menulist","field_checksum":"b9442e8d3b686067e1f5891fdd3e639f24e4220475cfe5d200df998d24cf7fd8","deeperlink":[{"title":"7.9.1 Delivering ART in maternal and child health-care settings","nid":608,"rid":2615,"weight":0,"parent_nid":592,"menu_type":"content","field_checksum":"a4ce188bdc463df28a6363046305e429631202fd4d6efafde75f56a9365c3860","prev_nid":592,"next_nid":609},{"title":"7.9.2 Delivering ART in TB treatment settings and TB treatment in HIV care settings","nid":609,"rid":2616,"weight":0,"parent_nid":592,"menu_type":"content","field_checksum":"33c87a013a4c9134dd3ef0617f0e5ac3bb4f0008b854c7eca2a2257dc5b3a233","prev_nid":608,"next_nid":610},{"title":"7.9.3 Integrating sexual and reproductive health services, including contraception, within HIV services","nid":610,"rid":2617,"weight":0,"parent_nid":592,"menu_type":"content","field_checksum":"f1c0cc4c7d60c557446b41d26238164339e9f3de371630973b12fa8cb87487c6","prev_nid":609,"next_nid":611},{"title":"7.9.4 Integrating diabetes and hypertension care with HIV care","nid":611,"rid":2618,"weight":0,"parent_nid":592,"menu_type":"content","field_checksum":"d44716c81d0f8b17e5d57afb4971a5923579e4c0e62c174daa44d48bf27451f4","prev_nid":610,"next_nid":612},{"title":"7.9.5 ART in settings providing opioid substitution therapy","nid":612,"rid":2619,"weight":0,"parent_nid":592,"menu_type":"content","field_checksum":"5b3e67e43d34a9c69dc07c2d118bfb295c35f19979bdd23badc0a3a698970843","prev_nid":611,"next_nid":613},{"title":"7.9.6 Diagnostic integration","nid":613,"rid":2620,"weight":0,"parent_nid":592,"menu_type":"content","field_checksum":"d4050398b3c98eaae6608c7d2c8a8c9af54c8c563ba62bfeab47eea69cd10778","prev_nid":612,"next_nid":593}],"prev_nid":591,"next_nid":608},{"title":"7.10 Delivering HIV services to children","nid":593,"rid":2790,"weight":9,"parent_nid":464,"menu_type":"content-menulist","field_checksum":"bbd064abafd6f4bbe70bbdcbfc83d253a9fffbdc5d34024adc10f7bb3f124485","deeperlink":[{"title":"7.10.1 Locate and link","nid":614,"rid":2585,"weight":0,"parent_nid":593,"menu_type":"content","field_checksum":"24d0b8def2d6de60eba76a9f2be33a7ef9d179e3d442e48bca84c95f9e7cef2f","prev_nid":593,"next_nid":615},{"title":"7.10.2 Treat","nid":615,"rid":2586,"weight":0,"parent_nid":593,"menu_type":"content","field_checksum":"285c1de5bf7e7967016e13bb467f29f1da944cb10388bd53f7f87532f8cf70a9","prev_nid":614,"next_nid":616},{"title":"7.10.3 Retain","nid":616,"rid":2791,"weight":0,"parent_nid":593,"menu_type":"content","field_checksum":"58f378c3d93b5ee1f40c9dffe4b11be3f224243d41e7a1106ba99fbd4b42aaa1","prev_nid":615,"next_nid":617},{"title":"7.10.4 Cross-cutting interventions along the continuum of care","nid":617,"rid":2624,"weight":0,"parent_nid":593,"menu_type":"content","field_checksum":"c2b1c0f137984ba2c4c7c41dcc10b8e71824dfb6b9aa22ead098af044fe68b22","prev_nid":616,"next_nid":594}],"prev_nid":613,"next_nid":614},{"title":"7.11 Service delivery for adolescents","nid":594,"rid":2740,"weight":10,"parent_nid":464,"menu_type":"content-menulist","field_checksum":"c61c67dc923b8347431a2a6a1ac26306e5756af913987775fab6f3e97933bad2","deeperlink":[{"title":"7.11.1 Delivering high-quality HIV services to adolescents","nid":618,"rid":2792,"weight":0,"parent_nid":594,"menu_type":"content","field_checksum":"e150953887a21ffff1c40915aff125259adf5ac58bc60f7278222d07f5caf298","prev_nid":594,"next_nid":619},{"title":"7.11.2 Psychosocial interventions for adolescents and young adults living with HIV","nid":619,"rid":2626,"weight":0,"parent_nid":594,"menu_type":"content","field_checksum":"2c2957d2b3cd6848d1a07c9ca4fcc6bb565f7e544d2ffb1e1ff9f4ad5342257b","prev_nid":618,"next_nid":595}],"prev_nid":617,"next_nid":618},{"title":"7.12 Improving the quality of HIV care services","nid":595,"rid":2795,"weight":11,"parent_nid":464,"menu_type":"content","field_checksum":"0e56d9fc8b2b735dd54d17a5640f15a5b0f2793a67837b23af8c70ceaf2c3abd","prev_nid":619,"next_nid":596},{"title":"7.13 Procurement and supply management systems for HIV health products","nid":596,"rid":2903,"weight":12,"parent_nid":464,"menu_type":"content","field_checksum":"a3764160d3823ae6744a191d47e48531ed9683e6581f7e537e46fce2a74adcc8","prev_nid":595,"next_nid":597},{"title":"7.14 Laboratory and diagnostic services","nid":597,"rid":2797,"weight":13,"parent_nid":464,"menu_type":"content","field_checksum":"d037169795bcadebfd1b93eb26b72e3cc06dcf975f3214f4040820dd28316f9b","prev_nid":596,"next_nid":598},{"title":"7.15 Laboratory connectivity ","nid":598,"rid":2634,"weight":14,"parent_nid":464,"menu_type":"content","field_checksum":"7ea7f0527f456c6dd9fa1d0322de02286d1163ecfc8a76b0b66aa05a7cefce4f","prev_nid":597,"next_nid":620},{"title":"References","nid":620,"rid":2904,"weight":15,"parent_nid":464,"menu_type":"content","field_checksum":"fc634447f7acb13c429669698099079e0d31183ec896c225195fc61fa67c5a13","prev_nid":598,"next_nid":621}]},{"title":"8. Monitoring Art Programme Functioning","nid":465,"rid":2959,"weight":10,"parent_nid":662,"menu_type":"menu_list","field_checksum":"4336aa8f05ed542bff0d3ab58e925f9b9270d451f087c5a65166adf9274cda04","deeperlink":[{"title":"8.1 Introduction","nid":621,"rid":2644,"weight":0,"parent_nid":465,"menu_type":"content","field_checksum":"8f1cce790611e4df9be1a34e8818daf4b29209906207b3ab17c1f8efd0e78d43","prev_nid":620,"next_nid":622},{"title":"8.2 Selection of key indicators to improve service delivery and assess impact","nid":622,"rid":2798,"weight":0,"parent_nid":465,"menu_type":"content","field_checksum":"d993388f34323a334201903aa91a28f6d3ff80be50523533f557421359aaec76","prev_nid":621,"next_nid":623},{"title":"8.3 Data collection and disaggregation","nid":623,"rid":2674,"weight":0,"parent_nid":465,"menu_type":"content","field_checksum":"eeeefaa3d7430ec901d67b5c6719ef29b72d2c76fd0b0d27ec387dd0b95dc631","prev_nid":622,"next_nid":624},{"title":"8.4 Strengthening data systems","nid":624,"rid":2799,"weight":0,"parent_nid":465,"menu_type":"content","field_checksum":"9857fb0e50257b195cb850d01065e68f2aa0cd023c5fd68f26348bc37177aa4d","prev_nid":623,"next_nid":625},{"title":"8.5 Evaluation, including impact and programme performance","nid":625,"rid":2707,"weight":0,"parent_nid":465,"menu_type":"content","field_checksum":"271bea5c40d43a9dfab3020b3b5f7a42e5fabd1b66f1da15fc4b3c89e3698a27","prev_nid":624,"next_nid":626},{"title":"8.6 Monitoring ARV drug toxicity","nid":626,"rid":2741,"weight":0,"parent_nid":465,"menu_type":"content-menulist","field_checksum":"94393f682ff4e269905a2e3893cc96d6f22ae32099462a674c61c9c2b148dc35","deeperlink":[{"title":"8.6.1 Routine monitoring for ARV toxicity","nid":628,"rid":2678,"weight":0,"parent_nid":626,"menu_type":"content","field_checksum":"d6e8cca40e4956c5eb9f735f813442542d7084bbe6de02bc9c3c2c518e78b1bd","prev_nid":626,"next_nid":629},{"title":"8.6.2 Longitudinal monitoring recommended to address emerging concerns and risk factors related to ARV drug toxicity","nid":629,"rid":2800,"weight":0,"parent_nid":626,"menu_type":"content","field_checksum":"a4effae3e78fa7fdf9c49e90180378bb07429622ac3456de9e011f22add83be7","prev_nid":628,"next_nid":630},{"title":"8.6.3 New indicators for routine monitoring of adverse pregnancy outcomes related to exposure to ARV drugs","nid":630,"rid":2680,"weight":0,"parent_nid":626,"menu_type":"content","field_checksum":"b2578efe11165fd6d99581ed22d06ce9427d4a4d73c415fc5e67960b1b930e58","prev_nid":629,"next_nid":631},{"title":"8.6.4 Global surveillance of the safety of ARV drugs for adults, children and adolescents and in pregnancy","nid":631,"rid":2681,"weight":0,"parent_nid":626,"menu_type":"content","field_checksum":"6742d9eb627128c1a9c04026423f54ca7e0902acc96c7705a9e7f6006aeda4fe","prev_nid":630,"next_nid":627}],"prev_nid":625,"next_nid":628},{"title":"8.7 HIV drug resistance","nid":627,"rid":2742,"weight":0,"parent_nid":465,"menu_type":"content-menulist","field_checksum":"d135409809b102e5afc54908ab8b35c8d9d094aacbd310cf24524e6d03977974","deeperlink":[{"title":"8.7.1 National action plans on HIV drug resistance","nid":632,"rid":2801,"weight":0,"parent_nid":627,"menu_type":"content","field_checksum":"66b97a13927c0fe76f222e3a8090f3ed6920c39f13609b4341fa0cc5dcb73ccb","prev_nid":627,"next_nid":633},{"title":"8.7.2 HIV drug resistance surveillance","nid":633,"rid":2683,"weight":0,"parent_nid":627,"menu_type":"content","field_checksum":"8fabc6c86913e7f04cd17fbbd360ed0bae9b11e89442e75548130e90edc6c330","prev_nid":632,"next_nid":634},{"title":"8.7.3 Routine monitoring of quality-of-care indicators and early warning indicators of HIV drug resistance","nid":634,"rid":2802,"weight":0,"parent_nid":627,"menu_type":"content","field_checksum":"a64967c7a37105faefdf1335e1a2e08831ce6403a2e277d8a73ddf67567165ab","prev_nid":633,"next_nid":635}],"prev_nid":631,"next_nid":632},{"title":"References","nid":635,"rid":2660,"weight":0,"parent_nid":465,"menu_type":"content","field_checksum":"88d59dabf54f53cd29a50f7664cca7bdb6f4fc54ea045b0e069f0107560d3e42","prev_nid":634,"next_nid":636}]},{"title":"9. Publicationm Dissemination and Evaluation","nid":466,"rid":2960,"weight":11,"parent_nid":662,"menu_type":"menu_list","field_checksum":"b178c71453b070c3041e8a88ef2cb79f6b5825654535dc9d5d4e3ece0833187d","deeperlink":[{"title":"9.1 Publication ","nid":636,"rid":2665,"weight":0,"parent_nid":466,"menu_type":"content","field_checksum":"fae9f0bcf5a7fef1e0c2eb0c612a43c922c884331fb3d199b5b8629fe658b502","prev_nid":635,"next_nid":637},{"title":"9.2 Dissemination and implementation","nid":637,"rid":2803,"weight":0,"parent_nid":466,"menu_type":"content","field_checksum":"f6b40588cfd0057e15d6560bdc4f9cce81a89c529a468b740b57ce7ea2cc0e3f","prev_nid":636,"next_nid":638},{"title":"9.3 Useful analytical tools for planning","nid":638,"rid":2686,"weight":0,"parent_nid":466,"menu_type":"content","field_checksum":"3e841af0910d330e1ad79ac4394ccada7dc682d3096f0e3147d0eaff43dc0f1c","prev_nid":637,"next_nid":639},{"title":"9.4 Evaluation","nid":639,"rid":2687,"weight":0,"parent_nid":466,"menu_type":"content","field_checksum":"e77677e1b157bf2afc30ac284e742603c69e515487374e9384134582b3510665","prev_nid":638,"next_nid":640},{"title":"References","nid":640,"rid":2905,"weight":0,"parent_nid":466,"menu_type":"content","field_checksum":"5feb31d8c0ab201ba07328c459f74af078e26e27c8f8e7afa42b09784d6ede92","prev_nid":639,"next_nid":467}]},{"title":"Glossary","nid":467,"rid":2961,"weight":12,"parent_nid":662,"menu_type":"content","field_checksum":"0802f33a3a9be1c94d07a104ed30418eaa0648e1df940ac43cdab4c3ada0adeb","prev_nid":640,"next_nid":685}]},{"title":"Other important guidelines","nid":663,"rid":2949,"weight":2,"parent_nid":453,"menu_type":"menu_list","field_checksum":"a578000a004e1ea668b12647a56bbbeb990942865b11fe7af5ab1faf03239731","deeperlink":[{"title":"Primary health care and HIV: convergent actions: policy considerations for decision-makers","nid":685,"rid":3061,"weight":-2,"parent_nid":663,"menu_type":"content","is_home":1,"field_checksum":"f039d8835ec675616d316d8c96eee61381730fba2b316def5933eafeb5e5a9a9","prev_nid":467,"next_nid":684},{"title":"Policy brief Virtual interventions in response to HIV, sexually transmitted infections and viral hepatitis Innovate\u2014Implement\u2014Integrate, 2022","nid":684,"rid":3062,"weight":-1,"parent_nid":663,"menu_type":"content","is_home":1,"field_checksum":"3b7920c1119866f46647acaf7a8d801139ba0e922aabc0adbbea2540025b0720","prev_nid":685,"next_nid":665},{"title":"Recommended package of interventions for HIV, viral hepatitis and STI prevention, diagnosis, treatment and care for people who inject drugs","nid":665,"rid":3063,"weight":0,"parent_nid":663,"menu_type":"content","is_home":1,"field_checksum":"b220b924e36dde4604698e212425631e6e81de21b4fc055e890fd18231dcade6","prev_nid":684,"next_nid":666},{"title":"Integrating the prevention and control of noncommunicable diseases in HIV\/AIDS, tuberculosis, and sexual and reproductive health programmes: implementation guidance","nid":666,"rid":3064,"weight":1,"parent_nid":663,"menu_type":"content","is_home":1,"field_checksum":"63496251fc3140b5996fd14641f65318e49c41c6384bbef15ca591f1f4db9090","prev_nid":665,"next_nid":667},{"title":"Governance for the validation of elimination of mother-to-child transmission of HIV, syphilis and hepatitis B virus: an overview of validation structures and responsibilities at national, regional and global levels","nid":667,"rid":3065,"weight":2,"parent_nid":663,"menu_type":"content","field_checksum":"034d94be7577f5b8a8589249f5aeba059f585e3ecf25685fb6c9669d4408e792","prev_nid":666,"next_nid":668},{"title":"Consolidated guidelines on HIV, viral hepatitis and STI prevention, diagnosis, treatment and care for key populations","nid":668,"rid":3081,"weight":3,"parent_nid":663,"menu_type":"content","field_checksum":"03deaf3cf7704790f6c1cd188eec63be9d05a2e840150daf45e6892fcdb2a787","prev_nid":667,"next_nid":669},{"title":"Consolidated guidelines on person-centred HIV strategic information: strengthening routine data for impact","nid":669,"rid":3067,"weight":5,"parent_nid":663,"menu_type":"content","field_checksum":"c2d8145dbf67a7bb81abc566a5855644f12268925ab6414c1cf8f14e5c632111","prev_nid":668,"next_nid":670},{"title":"Guidelines for diagnosing, preventing and managing cryptococcal disease among adults, adolescents and children living with HIV","nid":670,"rid":3068,"weight":6,"parent_nid":663,"menu_type":"content","field_checksum":"53cb5330dd00c4011a4aec6e80c4ae0c3115ac5fc113475056c40f80a3ad0614","prev_nid":669,"next_nid":671},{"title":"WHO guideline for the treatment of visceral leishmaniasis in HIV co-infected patients in East Africa and South-East Asia","nid":671,"rid":3069,"weight":7,"parent_nid":663,"menu_type":"content","field_checksum":"49c44952e796ca2b35006cf53c2c3e2969042e0293ae6d3a655c896163de5ada","prev_nid":670,"next_nid":672},{"title":"Digital adaptation kit for HIV: operational requirements for implementing WHO recommendations and standards within digital systems","nid":672,"rid":3070,"weight":8,"parent_nid":663,"menu_type":"content","field_checksum":"3bdbb2e7161c520bb025589350fdc0d123b49848860d014d0444f284d6116daa","prev_nid":671,"next_nid":673}]},{"title":"Meeting reports and technical documents","nid":664,"rid":2948,"weight":3,"parent_nid":453,"menu_type":"menu_list","field_checksum":"dd17ff7d59dfac25c350f83d6064d683fda2da97d0a1b0465714f35b459d2730","deeperlink":[{"title":"Report on the global action plan on HIV drug resistance 2017\u20132021","nid":673,"rid":3071,"weight":0,"parent_nid":664,"menu_type":"content","field_checksum":"8e76b17eba74607696a25214562411ce66ce78d2726366f82de82a346b27ce27","prev_nid":672,"next_nid":674},{"title":"Update on the transition to dolutegravir-based antiretroviral therapy","nid":674,"rid":3072,"weight":1,"parent_nid":664,"menu_type":"content","is_home":1,"field_checksum":"d8decd53c983dde97f3c3684279583b7abb423d721eab7af179fcfd116f050fb","prev_nid":673,"next_nid":675},{"title":"Priorities for antiretroviral drug optimization in adults and children report of a CADO, PADO and HIVResNet joint meeting","nid":675,"rid":3073,"weight":2,"parent_nid":664,"menu_type":"content","field_checksum":"cb3aafc1d613c571060bee3fb9a6cb007a65b2f0d10a26883d5471524637b165","prev_nid":674,"next_nid":676},{"title":"Report from the scoping consultation on severe bacterial infections among people with advanced HIV disease","nid":676,"rid":3074,"weight":3,"parent_nid":664,"menu_type":"content","field_checksum":"b5f04a321819fd13f1a139e4bbf0f9ecaae1fb3f8ebb652befcfcd10515fd305","prev_nid":675,"next_nid":677},{"title":"Providing care to people with advanced HIV disease who are seriously ill","nid":677,"rid":3075,"weight":4,"parent_nid":664,"menu_type":"content","field_checksum":"17fb5b9b9e1ad54ca5b14554b7003b15ba1aca9f0c3d94d20875d907f23d10df","prev_nid":676,"next_nid":678},{"title":"Sentinel surveys of acquired HIV resistance to dolutegravir among people receiving dolutegravir-containing antiretroviral therapy","nid":678,"rid":3076,"weight":5,"parent_nid":664,"menu_type":"content","field_checksum":"9ea91977c7d925a491971d48c071e25fce4643101f268b7a09f0b1a79831adcf","prev_nid":677,"next_nid":681},{"title":"Virtual workshop on postnatal prophylaxis to reach elimination of HIV vertical transmission: optimizing research and accelerating access to innovation","nid":681,"rid":3077,"weight":7,"parent_nid":664,"menu_type":"content","field_checksum":"0dec587d5721e991884d9ffdb77e28f704c0e73521acbeade1f4099cae3558f0","prev_nid":678,"next_nid":682},{"title":"Integration of mental health and HIV interventions","nid":682,"rid":3078,"weight":8,"parent_nid":664,"menu_type":"content","field_checksum":"9820e0fb24233c4613098e9c86b97cb410f0531496a3bda062d61d5ae0d0af09","prev_nid":681,"next_nid":454}]}]},{"title":"Summary Recommendations","nid":454,"rid":3002,"weight":-14,"icon":"","parent_nid":452,"menu_type":"content","field_checksum":"e8a711ab25681ebc73f0a15463597d21da7fa12a5c7f0e314b655be430883354","deeperlink":[{"title":"Chapter 2: HIV testing and diagnosis","nid":648,"rid":2837,"weight":0,"parent_nid":454,"menu_type":"accord","field_checksum":"07345fe519959d81c706cf81eb3d5e3a633bdda12754e62ff19d592c549daf80","prev_nid":454,"next_nid":649},{"title":"Chapter 3: HIV prevention","nid":649,"rid":2888,"weight":0,"parent_nid":454,"menu_type":"accord","field_checksum":"404efeb16b256753bda2a9aa02c86d71cb11c14e56f4f7e3167c5c4e9ecb372f","prev_nid":648,"next_nid":650},{"title":"Chapter 4: ART for people living with HIV","nid":650,"rid":2918,"weight":0,"parent_nid":454,"menu_type":"accord","field_checksum":"251804953c4054a11662d5583fb6651649ce643687008cc282cef5bbb950ef7b","prev_nid":649,"next_nid":651},{"title":"Chapter 5: Advanced HIV disease","nid":651,"rid":2861,"weight":0,"parent_nid":454,"menu_type":"accord","field_checksum":"c5a78340bdf7b8ddbb23503ef2b4b5424b9884365936cde81f22354ce883134c","prev_nid":650,"next_nid":652},{"title":"Chapter 6: Coinfections and comorbidities","nid":652,"rid":2864,"weight":0,"parent_nid":454,"menu_type":"accord","field_checksum":"c309c6a8541a6b6db62ba807cb7b3bedde06c4b9caa089c579c0bad73c27fa34","prev_nid":651,"next_nid":653},{"title":"Chapter 7: Service delivery","nid":653,"rid":2889,"weight":0,"parent_nid":454,"menu_type":"accord","field_checksum":"58461a833217863948988d3e5b1ca42ab8c42c386367042f8de9cd72ab96eb3d","prev_nid":652,"next_nid":642}],"prev_nid":682,"next_nid":648},{"title":"Annexes","nid":641,"rid":2939,"weight":0,"icon":"","parent_nid":452,"menu_type":"menu_list","field_checksum":"36337f142b27f7cb744c81f35f4594fcaa66c119c720deedbb47518de2e45c4f","deeperlink":[{"title":"Dosages For ARV Drugs","nid":642,"rid":2816,"weight":0,"parent_nid":641,"menu_type":"content","field_checksum":"8334c597fdcc8d5e50c417083c03f7c518ecd44847fc5c6549d1b2262e5cf9e9","prev_nid":653,"next_nid":644},{"title":"Key Drug Interaction For ARVS","nid":643,"rid":2919,"weight":0,"parent_nid":641,"menu_type":"menu_list","field_checksum":"d423d6e307b1caec0e5703edf14b2357f45cd4372251407ac214448885dbbc0f","deeperlink":[{"title":"Introduction","nid":644,"rid":3084,"weight":0,"parent_nid":643,"menu_type":"content","field_checksum":"16a952ccb7b7770af201e200a4145f667e64240dd14a70df8e4e6ea892967ba1","prev_nid":642,"next_nid":645},{"title":"Abbreviations","nid":645,"rid":2890,"weight":1,"parent_nid":643,"menu_type":"content","field_checksum":"0275c9a338b71946b3af1f86b710eaf8590916d622db6767d0c5f8d7aa4539c8","prev_nid":644,"next_nid":646},{"title":"Colour legend","nid":646,"rid":3089,"weight":2,"parent_nid":643,"menu_type":"content-menulist","field_checksum":"ef71ae65700650a4ad65d3e53ad2c1a7aa5a86d3ec8435547babae1c72984f87","deeperlink":[{"title":"Key drug interactions for ARVs - I","nid":687,"rid":3092,"weight":0,"parent_nid":646,"menu_type":"content","prev_nid":646,"next_nid":688},{"title":"Key drug interactions for ARVs - II","nid":688,"rid":3093,"weight":0,"parent_nid":646,"menu_type":"content","prev_nid":687,"next_nid":686},{"title":"Table A2.2 Footnotes","nid":686,"rid":3091,"weight":1,"parent_nid":646,"menu_type":"content","prev_nid":688,"next_nid":647}],"prev_nid":645,"next_nid":687}]},{"title":"References","nid":647,"rid":2818,"weight":0,"parent_nid":641,"menu_type":"content","field_checksum":"947b3ded844e7c943b003663433d3ef3d85cf5753237c038e905652f776abdd1","prev_nid":686}]}]}]